Advertisement

Annals of Nuclear Medicine

, Volume 33, Issue 1, pp 61–67 | Cite as

The role of 13N-ammonia in the differential diagnosis of gliomas and brain inflammatory lesions

  • Chang Yi
  • Xinchong Shi
  • Xuezhen Zhang
  • Ganhua Luo
  • Bing Zhang
  • Xiangsong ZhangEmail author
Original Article

Abstract

Objective

To investigate the utility of 13N-ammonia PET/CT imaging in the differential diagnosis of gliomas and brain inflammations.

Methods

13N-ammonia PET/CT imaging data of 77 patients with gliomas and 34 patients with brain inflammations were retrospectively analyzed. No patients received any treatment before 13N-ammonia imaging. All the patients were diagnosed by stereotactic biopsy or clinical follow-up. Visual and semi-quantitative analysis was performed to analyze the results of 13N-ammonia imaging. Finally, the uptake ratios of each lesion were calculated and its differences among different groups were tested with one-way ANOVA.

Results

29.4% inflammations, 51.6% low-grade gliomas and 91.3% high-grade gliomas were positive by visual analysis in 13N-ammonia imaging. The sensitivity, specificity and accuracy for the diagnosis of gliomas were 75.3%, 55.8% and 67.8%, respectively. As for semi-quantitative analysis, the T/G ratios of inflammatory lesions, low-grade gliomas and high-grade gliomas were 0.88 ± 0.24, 1.04 ± 0.43 and 1.43 ± 0.49, respectively. One-way ANOVA revealed that the T/G ratios of high-grade gliomas were significantly higher than those of low-grade gliomas and inflammations (P < 0.05), but there was no statistical difference between low-grade gliomas and inflammations (P = 0.118). Among the inflammatory lesions, T/G ratios were not statistically different between infectious and demyelinating lesions (P > 0.05). ROC curve analysis showed that the optimal cut-off value of T/G ratio in distinguishing gliomas from inflammations was 1.21 with the AUC 0.78. The sensitivity, specificity, accuracy, PPV and NPV were 52.9%, 94.4%, 65.3%, 95.7% and 45.9%, respectively. ROC curve analysis showed that the optimal cut-off value of T/G ratio in distinguishing high-grade gliomas from low-grade gliomas was 1.06 with the AUC 0.78. The sensitivity, specificity, accuracy, PPV and NPV were 81.5%, 67.7%, 76.5%, 81.5% and 67.7%, respectively. ROC curve analysis showed that the optimal cut-off value of T/G ratio in distinguishing high-grade gliomas from low-grade gliomas and inflammations was 1.19 with the AUC 0.84. The sensitivity, specificity, accuracy, PPV and NPV were 70.4%, 85.1%, 78.5%, 79.2% and 78.1%, respectively.

Conclusions

13N-ammonia imaging is effective in distinguishing high-grade gliomas from low-grade gliomas and inflammations, but its role in the differential diagnosis of low-grade gliomas and brain inflammatory lesions is limited, and the accuracy needs to be improved.

Keywords

Glioma Brain inflammation 13N-ammonia PET-CT 

Notes

Funding

This work was funded by Science and Technology Planning Project of Guangdong Province (2017B020210001), Science and Technology Program of Guangzhou (201607010353), Innovation Key Fund of Guangdong Province (2016B030307003), National Natural Science Foundation of China (81501509), Training program of the Major Research Plan of Sun Yat-Sen University (17ykjc10).

References

  1. 1.
    Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016;130:269–82.CrossRefGoogle Scholar
  2. 2.
    Hutterer M, Hattingen E, Palm C, Proescholdt MA, Hau P. Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol. 2015;17:784–800.CrossRefGoogle Scholar
  3. 3.
    Khan MN, Sharma AM, Pitz M, Loewen SK, Quon H, Poulin A, et al. High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol. 2016;23:e383–91.CrossRefGoogle Scholar
  4. 4.
    Knudsen-Baas KM, Moen G, Fluge O, Storstein A. Pseudoprogression in high-grade glioma. Acta Neurol Scand Suppl. 2013;127(196):31–37.CrossRefGoogle Scholar
  5. 5.
    Galldiks N, Langen KJ, Pope WB. From the clinician’s point of view—what is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015;17:1434–44.CrossRefGoogle Scholar
  6. 6.
    Puttick S, Bell C, Dowson N, Rose S, Fay M. PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today. 2015;20:306–17.CrossRefGoogle Scholar
  7. 7.
    Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol. 2013;34:944–50. (S941–911).CrossRefGoogle Scholar
  8. 8.
    Kawai N, Okauchi M, Miyake K, Sasakawa Y, Yamamoto Y, Nishiyama Y, et al. 11C-methionine positron emission tomography in nontumorous brain lesions. No ShinkeiGeka. 2010;38(11):985–95.Google Scholar
  9. 9.
    Demetriades AK, Almeida AC, Bhangoo RS, Barrington SF. Applications of positron emission tomography in neuro-oncology: a clinical approach. Surgeon. 2014;12:148–57.CrossRefGoogle Scholar
  10. 10.
    Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516–24.CrossRefGoogle Scholar
  11. 11.
    Rapp M, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ, et al. Clinical value of O-(2-[(18)F]-fluoroethyl)-l-tyrosine positron emission tomography in patients with low-grade glioma. Neurosurg Focus. 2013;34:E3.CrossRefGoogle Scholar
  12. 12.
    Shi X, Liu Y, Zhang X, Yi C, Wang X, Chen Z, et al. The comparison of 13 N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med. 2013;38:522–6.CrossRefGoogle Scholar
  13. 13.
    Shi X, Yi C, Wang X, Zhang B, Chen Z, Tang G, et al. 13 N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med. 2015;40:195–9.CrossRefGoogle Scholar
  14. 14.
    Xiangsong Z, Changhong L, Weian C, Dong Z. PET Imaging of cerebral astrocytoma with 13 N-ammonia. J Neurooncol. 2006;78:145–51.CrossRefGoogle Scholar
  15. 15.
    Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C. 13 N-ammonia versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011;36:1003–6.CrossRefGoogle Scholar
  16. 16.
    Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ. The role of surgery in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2015;125:503–30.CrossRefGoogle Scholar
  17. 17.
    Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas? Neurosurgery. 2015;77:663–73.CrossRefGoogle Scholar
  18. 18.
    Cooper AJ. 13N as a tracer for studying glutamate metabolism. Neurochem Int. 2011;59:456–64.CrossRefGoogle Scholar
  19. 19.
    Keiding S, Sorensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13 N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology. 2006;43:42–50.CrossRefGoogle Scholar
  20. 20.
    Momosaki S, Ito M, Tonomura M, Abe K. Assessment of glutamine synthetase activity by [13N]ammonia uptake in living rat brain. Synapse. 2015;69:26–32.CrossRefGoogle Scholar
  21. 21.
    Hu LS, Eschbacher JM, Dueck AC, Heiserman JE, Liu S, Karis JP, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol. 2012;33:69–76.CrossRefGoogle Scholar
  22. 22.
    Vajkoczy P, Schilling L, Ullrich A, Schmiedek P, Menger MD. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J Cereb Blood Flow Metab. 1998;18:510–20.CrossRefGoogle Scholar
  23. 23.
    Levashova Z, Backer M, Backer JM, Blankenberg FG. Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J Nucl Med. 2009;50:2058–63.CrossRefGoogle Scholar
  24. 24.
    Szade A, Grochot-Przeczek A, Florczyk U, Jozkowicz A, Dulak J. Cellular and molecular mechanisms of inflammation-induced angiogenesis. IUBMB Life. 2015;67:145–59.CrossRefGoogle Scholar
  25. 25.
    Bode JG, Peters-Regehr T, Kubitz R, Haussinger D. Expression of glutamine synthetase in macrophages. J Histochem Cytochem. 2000;48:415–22.CrossRefGoogle Scholar
  26. 26.
    Gras G, Porcheray F, Samah B, Leone C. The glutamate–glutamine cycle as an inducible, protective face of macrophage activation. J Leukoc Biol. 2006;80:1067–75.CrossRefGoogle Scholar
  27. 27.
    Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, et al. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. Cochrane Datab Syst Rev. 2018;1:CD011551.Google Scholar
  28. 28.
    Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics. 2009;6(3):465–77.CrossRefGoogle Scholar
  29. 29.
    Akimoto J. Immunohistochemical study of glutamine synthetase expression in normal human brain and intracranial tumors. No To Shinkei. 1993;45:362–8.Google Scholar
  30. 30.
    Li D, Zhao X, Zhang L, Li F, Ji N, Gao Z, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study. Mol Pharm. 2014;11:3923–9.CrossRefGoogle Scholar
  31. 31.
    Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180–2.Google Scholar
  32. 32.
    Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014;55:198–203.CrossRefGoogle Scholar
  33. 33.
    Sala Q, Metellus P, Taieb D, Kaphan E, Figarella-Branger D, Guedj E. 18F-DOPA, a clinically available PET tracer to study brain inflammation? Clin Nucl Med. 2014;39:e283–5.CrossRefGoogle Scholar
  34. 34.
    McCormick D, McQuaid S, McCusker C, Allen IV. A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol. 1990;16(3):205–11.CrossRefGoogle Scholar
  35. 35.
    Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13 N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013;38:98–102.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2018

Authors and Affiliations

  • Chang Yi
    • 1
  • Xinchong Shi
    • 1
  • Xuezhen Zhang
    • 2
  • Ganhua Luo
    • 1
  • Bing Zhang
    • 1
  • Xiangsong Zhang
    • 1
    Email author
  1. 1.Department of Nuclear MedicineThe First Affiliated Hospital of Sun Yat-Sen UniversityGuangzhouChina
  2. 2.Department of Nuclear MedicineThe No.1 People’s hospital of FoshanFoshanChina

Personalised recommendations